NCT00755859

Brief Summary

In a previous trial the investigators found that the effect of steroids in IgA nephropathy diminish over time. The difference in renal survival is striking up till the third year, but then remains constant. A six-month course of steroid therapy may be not enough to ensure a stable remission. The investigators hypothesized that a more aggressive treatment may obtain long-term better results. The investigators conducted a randomised controlled trial to assess the utility of low-dose azathioprine added to steroids in adult IgAN patients.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
206

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started May 1998

Longer than P75 for phase_4

Geographic Reach
2 countries

28 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 1998

Completed
6.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2004

Completed
2.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2007

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

September 18, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 19, 2008

Completed
Last Updated

September 19, 2008

Status Verified

August 1, 2008

Enrollment Period

6.6 years

First QC Date

September 18, 2008

Last Update Submit

September 18, 2008

Conditions

Keywords

IgA nephropathysteroidsazathioprinechronic kidney disease progressionproteinuria

Outcome Measures

Primary Outcomes (1)

  • progression of renal disease, estimated by the time to 50% increase in plasma creatinine from baseline.

    Every month for the first six months, then six months

Secondary Outcomes (2)

  • evolution of proteinuria over time

    every months for the first six months and then every six months

  • safety

    every months for the first six months and then every six months

Study Arms (2)

1

EXPERIMENTAL

Six month steroid course plus azathioprine

Drug: steroids plus azathioprine

2

ACTIVE COMPARATOR

six month steroid course

Drug: steroids

Interventions

methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months

Also known as: solumedrol, deltacortene, azatioprina
1

methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months

Also known as: solumedrol, deltacortene
2

Eligibility Criteria

Age16 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • biopsy proven IgA nephropathy
  • creatinine ≤ 2.0 mg/dl for at least three months
  • proteinuria ≥ 1.0 g/day for at least three months

You may not qualify if:

  • treatment with steroids or cytotoxic drugs during the previous three years
  • contraindications to steroids or azathioprine
  • Henoch-Schöenlein purpura
  • diabetes mellitus
  • severe hypertension (diastolic blood pressure \> 120 mmHg)
  • lupus erythematosus systemicus
  • malignancies
  • active peptic-ulcer disease
  • pregnancy
  • viral hepatitis or other infections

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (28)

Hospital "Bolognini"

Seriate, BG, Italy

Location

Hospital "Spedali Civili"

Brescia, Brescia, Italy

Location

Hospital of Montichiari

Montichiari, Brescia, Italy

Location

"G. Brotzu" Hospital

Cagliari, Cagliari, Italy

Location

Hospital "Cannizzaro"

Catania, Catania, Italy

Location

Hospital "S.Anna"

Como, CO, 22100, Italy

Location

Hospital "Istituti Ospitalieri"

Cremona, CR, Italy

Location

Hospital "S.Marta e S.Venera",

Acireale, CT, Italy

Location

Hospital "S.Vincenzo"

Taormina, CT, Italy

Location

Hospital "Careggi"

Florence, Firenze, Italy

Location

Hospital of University

Foggia, Foggia, Italy

Location

Department of Nephrology and Dialysis, A. Manzoni Hospital

Lecco, LC, 23900, Italy

Location

Hospital "Maggiore"

Lodi, LO, Italy

Location

Hospital "C. Poma"

Mantova, Mantova, Italy

Location

Hospital "Uboldo"

Cernusco sul Naviglio, MI, Italy

Location

Hospital of Desio

Desio, MI, Italy

Location

Hospital "Maggiore" IRCCS

Milan, MI, Italy

Location

Hospital "S. Francesco"

Nuoro, Nuoro, Italy

Location

Hospital "A.Segni"

Ozieri, Nuoro, Italy

Location

Hospital "V. Cervello"

Palermo, Palermo, Italy

Location

University Hospital

Parma, Parma, Italy

Location

Fondazione Maugeri" IRCCS

Pavia, Pavia, Italy

Location

CNR-IBIM

Reggio Calabria, Reggio Calabria, Italy

Location

Hospital "S. Maria Nuova"

Reggio Emilia, Reggio Emilia, Italy

Location

Hospital of Sondrio

Sondrio, Sondrio, Italy

Location

CMID

Torino, Torino, Italy

Location

Hospital "Belcolle"

Viterbo, Viterbo, Italy

Location

Inselspital

Bern, Switzerland

Location

Related Publications (1)

  • Locatelli F, Pozzi C, Del Vecchio L, Andrulli S, Pani A, Fogazzi G, Altieri P, Ponticelli C. Combined treatment with steroids and azathioprine in IgA nephropathy: design of a prospective randomised multicentre trial. J Nephrol. 1999 Sep-Oct;12(5):308-11.

    PMID: 10630693BACKGROUND

MeSH Terms

Conditions

Glomerulonephritis, IGAProteinuria

Interventions

SteroidsAzathioprineMethylprednisolone HemisuccinatedeltacorteneAdenosine Triphosphate

Condition Hierarchy (Ancestors)

GlomerulonephritisNephritisKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesAutoimmune DiseasesImmune System DiseasesUrination DisordersUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Fused-Ring CompoundsPolycyclic CompoundsThionucleosidesSulfur CompoundsOrganic ChemicalsMercaptopurinePurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsNucleosidesNucleic Acids, Nucleotides, and NucleosidesMethylprednisolonePrednisolonePregnadienetriolsPregnadienesPregnanesAdenine NucleotidesPurine NucleotidesNucleotidesRibonucleotides

Study Officials

  • Claudio Pozzi, MD

    A Manzoni Hospital, Lecco, Italy

    PRINCIPAL INVESTIGATOR
  • Francesco Locatelli, MD

    A Manzoni Hospital, Lecco, Italy

    STUDY CHAIR
  • Simeone Andrulli, MD

    A Manzoni Hospital, Lecco, Italy

    STUDY DIRECTOR
  • Antonello Pani, MD

    Hospital "G. Brotzu", Cagliari, Italy

    STUDY DIRECTOR
  • Paolo Altieri, MD

    Hospital "G. Brotzu", Cagliari, Italy

    STUDY DIRECTOR
  • Gian B Fogazzi, MD

    Hospital "Maggiore" IRCCS, Milan, Italy

    STUDY DIRECTOR
  • Claudio Ponticelli, MD

    Hospital "Maggiore" IRCCS, Milan, Italy

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 18, 2008

First Posted

September 19, 2008

Study Start

May 1, 1998

Primary Completion

December 1, 2004

Study Completion

September 1, 2007

Last Updated

September 19, 2008

Record last verified: 2008-08

Locations